Friedreich's Ataxia Program
Children and young adults with Friedreich's ataxia (FA) will find dedicated, expert care at Children’s Hospital of Philadelphia’s Friedreich's Ataxia Program. Our program is part of the Friedreich’s Ataxia Center of Excellence, a first-of-its-kind collaboration of leading FA experts committed to promoting FA research and clinical care. From initial diagnosis and testing through long-term disease management, we provide comprehensive care for children and adults from all over the world with this rare, progressive neurogenetic condition. Our aim is to provide you or your child with the best clinical care available and advance research to improve the lives of all individuals with FA.
FDA Approves First Drug for Friedreich’s Ataxia
The drug, omaveloxolone, is a once-a-day pill that will help improve neurological function and slow progression of the neurodegenerative disease.
Why Choose Us?
At Children’s Hospital of Philadelphia’s Friedreich’s Ataxia Program, children have access to top-notch clinical care and cutting-edge research opportunities in one place. As part of the Friedreich’s Ataxia Center of Excellence and the largest FA clinical program in the world, we are uniquely equipped to provide the specialized care patients with this rare, complex disease need. Learn more about our commitment to helping patients with FA and what it means to be a Center of Excellence.
Our team of FA experts provides comprehensive care, from initial diagnosis and testing through long-term disease management.